Acute renal failure with the combined use of rosuvastatin and fenofibrate

Abstract

Among the lipid-lowering drugs, the statins and fibrates are the most commonly used agents. Either class of drug is considered relatively safe. Though a variety of albeit uncommon adverse side effects have been observed with both classes, most of these therapeutic complications can be managed without discontinuation of the offending drug. Sometimes, especially in patients with extremely high cholesterol and/or triglyceride levels, a combination regimen is deemed necessary. However, the combined use of lipid-lowering drugs increases the incidence and severity of adverse events. In this article, we report an unusual case of acute renal failure (ARF) in a patient who had been prescribed both a statin (rosuvastatin) and a fibrate (fenofibrate).

Supplementation with the Extract of Schisandrae Fructus Pulp, Seed, or Their Combination Influences the Metabolism of Lipids and Glucose in Mice Fed with Normal and Hypercholesterolemic Diet

“…Although much effort has been put to develop drugs used for the prevention and treatment of HLD-related diseases, effective drugs for treating HLD, especially NAFLD, are yet to be discovered. In addition, synthetic lipid-lowering drugs have many potential adverse/side effects, such as muscle tenderness [10, 11], renal failure [12], and others, including headache, bowel upset, nausea, sleep disturbances, and hepatomegaly [13, 14]. In recent years, people prefer to use natural remedy such as dietary supplement/functional food for the prevention and treatment of NAFLD and/or lipid disorders [15, 16].…”

Drug Class Combination–Associated Acute Kidney Injury

“…Overall, reports of 56 combinations (73.7%) were considered VL quality ; 12 combinations (15.8%) were considered L quality. 10,11,[75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94] There were 8 (10.5%) combinations of M quality, 26,33,80,[95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114] and no study was ranked as being of high quality. Of the combinations, 58 (76%) had a single article for review.…”

“…Five case reports met inclusion criteria for the drug class combination of statins and fenofibrate, with 6 unique drug combinations evaluated. [10][11][12][13][14] The nephrotoxicity of this combination is theorized to result through the development of rhabdomyolysis. [39][40][41] It is unclear if this is a result of an interaction at the skeletal muscle or through a CYP450-mediated drug interaction.…”